Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2010-023026-20 | EudraCT Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Multiple-dose nicotine pharmacokinetics with three oral nicotine replacement products. A study in healthy smokers.
Fifty (50) healthy male or female subjects between the ages of 19 and 50 years, inclusive, smoking at least 20 cigarettes daily during at least one year preceding inclusion. Multiple doses of all study treatments are given either every 60 minutes or every 90 minutes, respectively. All products will be administered in accordance with labeling, on five separate treatment visits. The subjects will abstain from smoking from 8 pm in the evening before and until the end of each visit.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| NRT 60 | Experimental | A 6 mg dose of an experimental Nicotine Replacement Therapy (NRT) given every hour for 11 hours, with a 36-hour washout between visits |
|
| NFG 60 | Active Comparator | A 4 mg dose of a marketed Nicotine Fruit Gum (NFG) given every hour for 11 hours, with a 36-hour washout between visits |
|
| NRT 90 | Experimental | A 6 mg dose of NRT given every 90 minutes for 10.5 hours, with a 36-hour washout between visits |
|
| NFG 90 | Active Comparator | A 4 mg dose of NFG given every 90 minutes for 10.5 hours, with a 36-hour washout between visits |
|
| NIQ 60 | Active Comparator | A 4 mg dose of marketed nicotine mint lozenge (NIQ), given every hour for 11 hours, with a 36-hour washout between visits |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Nicotine | Drug | 6 mg experimental Nicotine Replacement Therapy (NRT) |
|
| Measure | Description | Time Frame |
|---|---|---|
| Maximum Observed Plasma Concentration | Maximum Observed Plasma Concentration (Cmax), which is the maximum (peak) concentration (amount of drug) measurable in blood plasma within the last dosing interval, measured in nanograms/milliliter (ng/mL) | within the last dosing interval (starting at 10.5-11 hours after first product administration) |
| Average Concentration | Average Nicotine Plasma Concentration (Cav) within the last dosing interval | within the last dosing interval (starting at 10.5-11 hours after first product administration) |
| Area Under the Curve | Area under the nicotine plasma concentration-vs.-time curve during the last dosing interval (AUCt) | within the last dosing interval (starting at 10.5-11 hours after first product administration) |
| Measure | Description | Time Frame |
|---|---|---|
| Time of Maximum Concentration | The time at which maximum concentration is reached (Tmax) | During 12 hours post-dose |
| Minimum Observed Concentration | Minimum Observed Plasma Concentration (Cmin), which is the minimum concentration (amount of drug) measurable in blood plasma within the last dosing interval, measured in nanograms/milliliter (ng/mL) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Elisabeth Kruse, PhD | McNeil AB | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| McNeil AB Clinical Pharmacology R&D | Lund | SE-222 20 | Sweden |
Not provided
| ID | Term |
|---|---|
| D014029 | Tobacco Use Disorder |
| D016540 | Smoking Cessation |
| ID | Term |
|---|---|
| D019966 | Substance-Related Disorders |
| D064419 | Chemically-Induced Disorders |
| D001523 | Mental Disorders |
| D015438 | Health Behavior |
Not provided
Not provided
| ID | Term |
|---|---|
| D009538 | Nicotine |
| ID | Term |
|---|---|
| D012991 | Solanaceous Alkaloids |
| D000470 | Alkaloids |
| D006571 | Heterocyclic Compounds |
| D011725 | Pyridines |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Nicotine | Drug | 4 mg marketed Nicotine Fruit Gum (NFG) |
|
|
| Nicotine | Drug | 4 mg marketed nicotine mint lozenge (NIQ) |
|
|
| within the last dosing interval (starting at 10.5-11 hours after first product administration) |
| Peak-Trough Fluctuation | Percent of Peak-Trough Fluctuation in one dosing interval at steady state (PTF) | within the last dosing interval (starting at 10.5-11 hours after first product administration) |
| Swing | Swing in one dosing interval at steady state, calculated as (Cmax-Cmin)/ Cmin | within the last dosing interval (starting at 10.5-11 hours after first product administration) |
| Nicotine Released | The amount of nicotine released from the product during product administration | 30 minutes |
| D001519 | Behavior |
| D006573 |
| Heterocyclic Compounds, 1-Ring |